These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 28831825)

  • 1. PDL-1/PD1 inhibitors: antibody or antinobody?
    Aoun F; Rassy EE; Assi T; Kattan J
    Future Oncol; 2017 Aug; 13(19):1669-1671. PubMed ID: 28831825
    [No Abstract]   [Full Text] [Related]  

  • 2. Inhibitors of the PD-1 Pathway in Tumor Therapy.
    LaFleur MW; Muroyama Y; Drake CG; Sharpe AH
    J Immunol; 2018 Jan; 200(2):375-383. PubMed ID: 29311378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Biomarkers predictive of PD1/PD-L1 immunotherapy in non-small cell lung cancer].
    Lupo A; Alifano M; Wislez M; Boulle G; Velut Y; Biton J; Cremer I; Goldwasser F; Leroy K; Damotte D
    Rev Pneumol Clin; 2018 Oct; 74(5):339-350. PubMed ID: 30337201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thymic malignancies: Twisting between autoimmunity and immunotherapy.
    Girard N
    Lung Cancer; 2017 Aug; 110():68-70. PubMed ID: 28526140
    [No Abstract]   [Full Text] [Related]  

  • 5. Preface: More than two decades of modern tumor immunology.
    Galluzzi L; Rudqvist NP
    Methods Enzymol; 2019; 629():xxi-xl. PubMed ID: 31727259
    [No Abstract]   [Full Text] [Related]  

  • 6. Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy.
    Constantinidou A; Alifieris C; Trafalis DT
    Pharmacol Ther; 2019 Feb; 194():84-106. PubMed ID: 30268773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive Efficacy Biomarkers of Programmed Cell Death 1/Programmed Cell Death 1 Ligand Blockade Therapy.
    Fang XN; Fu LW
    Recent Pat Anticancer Drug Discov; 2016; 11(2):141-51. PubMed ID: 26916881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Masterful Antibodies: Checkpoint Blockade.
    Lonberg N; Korman AJ
    Cancer Immunol Res; 2017 Apr; 5(4):275-281. PubMed ID: 28373215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Checkpoint blockade after kidney transplantation.
    Lesouhaitier M; Dudreuilh C; Tamain M; Kanaan N; Bailly E; Legoupil D; Deltombe C; Perrin P; Manson G; Vigneau C; Houot R
    Eur J Cancer; 2018 Jun; 96():111-114. PubMed ID: 29705511
    [No Abstract]   [Full Text] [Related]  

  • 10. Durvalumab in non-small-cell lung cancer patients: current developments.
    Mezquita L; Planchard D
    Future Oncol; 2018 Feb; 14(3):205-222. PubMed ID: 29140105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is it possible to rechallenge with PD-1/PD-L1 inhibitors after progression?
    Saleh K; Khalifeh-Saleh N; Kourie HR
    Immunotherapy; 2018 Apr; 10(5):345-347. PubMed ID: 29473468
    [No Abstract]   [Full Text] [Related]  

  • 12. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
    Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X
    Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Checkpoint PD-1/PD-L1: Is There Life Beyond Antibodies?
    Konstantinidou M; Zarganes-Tzitzikas T; Magiera-Mularz K; Holak TA; Dömling A
    Angew Chem Int Ed Engl; 2018 Apr; 57(18):4840-4848. PubMed ID: 29178534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive Biomarkers for Immunotherapy Response Beyond PD-1/PD-L1.
    Darabi S; Braxton DR; Eisenberg BL; Demeure MJ
    Oncology (Williston Park); 2020 Aug; 34(8):321-327. PubMed ID: 32785929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer.
    Shien K; Papadimitrakopoulou VA; Wistuba II
    Lung Cancer; 2016 Sep; 99():79-87. PubMed ID: 27565919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of immune checkpoint blockade for brain metastases.
    Harary M; Reardon DA; Iorgulescu JB
    CNS Oncol; 2019 Jun; 8(2):CNS33. PubMed ID: 30854898
    [No Abstract]   [Full Text] [Related]  

  • 17. Outside the box of immunotherapy - new hope for patients with advanced urothelial cancer.
    Ullén A
    Acta Oncol; 2019 Jul; 58(7):951-952. PubMed ID: 31232133
    [No Abstract]   [Full Text] [Related]  

  • 18. In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies?
    Aspeslagh S; Matias M; Palomar V; Dercle L; Lanoy E; Soria JC; Postel-Vinay S
    Eur J Cancer; 2017 Dec; 87():65-74. PubMed ID: 29126088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy for head and neck cancers: an update and future perspectives.
    Doescher J; Laban S; Schuler PJ; Brunner C; Hoffmann TK
    Immunotherapy; 2019 May; 11(7):561-564. PubMed ID: 30943860
    [No Abstract]   [Full Text] [Related]  

  • 20. [Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers].
    Duruisseaux M; Rouquette I; Adam J; Cortot A; Cazes A; Gibault L; Damotte D; Lantuejoul S
    Ann Pathol; 2017 Feb; 37(1):61-78. PubMed ID: 28162296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.